The volume and complexity of clinical data are growing at a faster pace than the industry can manage. Pharma companies large and small are seeing significant increases in end-of-study timelines….
“Quantitative decision-making with data rather than empirical thinking” – Certara’s Modeling & Simulation technology contributes to accelerate new drug development Certara G.K. held an online press seminar on Wednesday, August…
Have you heard the buzz around the new European Union Clinical Trial Regulations (EU-CTR) for transparency and disclosure of clinical trial data? The goal of the EU-CTR is to create…
Part 2 of this blog series dives further into the June 2022 podcast with R&D World editors, Paul Heney and Aimee Kalnoskas, having their minds blown — multiple times! —…
Human mass-balance studies are also called “C-14 studies” or “Absorption, Metabolism, and Excretion (AME) studies.” Drug developers conduct these studies of radiolabeled drugs to quantify the routes of elimination of…
R&D World editors, Paul Heney and Aimee Kalnoskas, have their minds blown — multiple times! — in this June 2022 Podcast, which delves into Certara’s Simcyp COVID-19 Vaccine Model, a…
Pharmaceutical companies should seize opportunities to digitally engage with payers globally using both face-to-face and interactive remote engagement tools.
PRINCETON, N.J.— July 12, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2022 after the…
© 2025 Certara. All Rights Reserved. | Privacy policy
